Bill Text: NY S06999 | 2015-2016 | General Assembly | Introduced

---

Bill Title: Amends the dosing limitations and medical conditions permitting the use of medical marihuana.

Spectrum: Partisan Bill (Democrat 2-0)

Status: (Introduced - Dead) 2016-03-15 - REFERRED TO HEALTH [S06999 Detail]

Download: New_York-2015-S06999-Introduced.html

---

                STATE OF NEW YORK
        ________________________________________________________________________
                                          6999
                    IN SENATE
                                     March 15, 2016
                                       ___________
        Introduced  by  Sen.  SAVINO -- read twice and ordered printed, and when
          printed to be committed to the Committee on Health
        AN ACT to amend the public health law, in relation to dosing limitations
          and medical conditions permitting the medical use of marihuana
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
     1    Section 1. Subdivision 15 of section 3360 of the public health law, as
     2  added by chapter 90 of the laws of 2014, is amended to read as follows:
     3    15.  "Individual dose" means a single measure of raw medical marihuana
     4  or non-infused concentrates to be determined and clearly identified by a
     5  patient's practitioner for the patient's specific  certified  condition.
     6  [For ingestible or sub-lingual medical marihuana products, no individual
     7  dose may contain more than ten milligrams of tetrahydrocannabinol.]
     8    §  2. Subdivision 7 of section 3360 of the public health law, as added
     9  by chapter 90 of the laws of 2014, is amended to read as follows:
    10    7. [(a)] "Serious condition" means:
    11    (i) having one of the following severe debilitating or  life-threaten-
    12  ing conditions: cancer, positive status for human immunodeficiency virus
    13  or  acquired  immune deficiency syndrome, amyotrophic lateral sclerosis,
    14  Alzheimer's  disease,  traumatic  brain  injury,  dystonia,  Parkinson's
    15  disease,  multiple  sclerosis, muscular dystrophy, damage to the nervous
    16  tissue of the spinal cord  with  objective  neurological  indication  of
    17  intractable  spasticity,  epilepsy,  wasting  syndrome,  post  traumatic
    18  stress  disorder,  rheumatoid  arthritis,  lupus,   inflammatory   bowel
    19  disease,  neuropathies, Huntington's disease, or as added by the commis-
    20  sioner; [and] or
    21    (ii) any of the following conditions where it is clinically associated
    22  with, or a complication of, a condition  under  this  paragraph  or  its
    23  treatment:  cachexia or wasting syndrome; severe or chronic pain; severe
    24  nausea; seizures; severe or persistent muscle spasms; or such conditions
    25  as are added by the commissioner.
    26    [(b) No later than eighteen months from the  effective  date  of  this
    27  section,  the  commissioner shall determine whether to add the following

         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD13610-02-6